Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

Inclusion Criteria:

1. Subjects must have histologically confirmed metastatic pancreatic ductal
adenocarcinoma.. Prior chemotherapy and/or radiotherapy either in the adjuvant or
neoadjuvant setting or for metastatic disease is not allowed.

2. Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue (from either the
primary tumor, locoregional disease or a metastatic site), either fresh
core-needle-biopsied or archived (two FFPE cores preferred whenever possible). If
fresh tissue is obtained, the core biopsy must be done at least 7 days prior to
randomization.

3. Age ≥21 years

4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 5. Measurable
disease per RECIST v1.1

5. Adequate organ and marrow function

6. Signed Informed Consent Form

7. For women of childbearing potential, agreement to use two effective forms of
contraception

Exclusion Criteria:

1. Subjects with a neuroendocrine tumor of the pancreas, an acinar tumor of the pancreas
or a pancreatic tumor with mixed histologies.

2. Subjects receiving heparin, warfarin, factor Xa inhibitors or other similar
anticoagulants. Note: Subjects may be receiving low-dose aspirin and/or non-steroidal
anti-inflammatory agents.

3. Subjects with brain metastases, leptomeningeal disease, uncontrolled seizure disorder,
or active neurologic disease

4. Subjects with Grade >2 peripheral neuropathy

5. Subjects with clinically significant ascites

6. Malignancies other than pancreatic cancer successfully treated within 3 years prior to
randomization, except for adequately treated carcinoma in situ of the cervix, basal or
squamous cell skin cancer, treated superficial bladder cancer, localized prostate
cancer treated surgically with curative intent, ductal carcinoma in situ treated
surgically with curative intent

7. Significant intercurrent illness that will limit the patient's ability to participate
in the study or may result in their death over the next 18 months

8. History of a significant allergic reaction attributed to humanized or human monoclonal
antibody therapy

9. Subjects with known clinically significant gastrointestinal disease including, but not
limited to, inflammatory bowel disease

10. Pregnant women or nursing women

11. Subjects with known HIV infection

12. Known bleeding disorder or coagulopathy